Home Featured Page 205

Featured

Latest

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

PharmaDrug Expands Product Offering to Prepare for Potential Adult Use Market...

Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT...

Psychedelic Bulletin: MindMed Announces R(-)-MDMA Program; Psilocybin for Anxiety Study Secures...

PTSF83 – Abuse in Psychedelics: Complicity and Groupthink

Addressing Abuse in Psychedelic Spaces

MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol...

Awakn Life Sciences Identifies New Chemical Series via Its Drug Discovery...

Cybin Announces Launch of EMBARK Psychedelic Facilitator Training Program

MYND Life Sciences Signs Agreement to Acquire Rights for the Use...

Entheon Biomedical Provides Corporate Update on Studies and Clinical Trials

1...204205206...296 Page 205 of 296

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

PharmaDrug Expands Product Offering to Prepare for Potential Adult Use Market...

Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT...

Psychedelic Bulletin: MindMed Announces R(-)-MDMA Program; Psilocybin for Anxiety Study Secures...

PTSF83 – Abuse in Psychedelics: Complicity and Groupthink

Addressing Abuse in Psychedelic Spaces

MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol...

Awakn Life Sciences Identifies New Chemical Series via Its Drug Discovery...

Cybin Announces Launch of EMBARK Psychedelic Facilitator Training Program

MYND Life Sciences Signs Agreement to Acquire Rights for the Use...

Entheon Biomedical Provides Corporate Update on Studies and Clinical Trials

EDITOR PICKS

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY